|
Published by: Global Markets Direct
Published: Sep. 25, 2012 - 281 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Asthma Overview
- Therapeutics Development
- An Overview of Pipeline Products for Asthma
- Asthma Therapeutics under Development by Companies
- Asthma Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Asthma Therapeutics – Products under Development by Companies
- Asthma Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Asthma Therapeutics Development
- Alcon, Inc.
- Johnson & Johnson
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Kyowa Hakko Kirin Co., Ltd.
- Abbott Laboratories
- Amgen Inc.
- AstraZeneca PLC
- GlaxoSmithKline plc
- Genentech, Inc.
- Biotec Pharmacon ASA
- MedImmune LLC
- Daiichi Sankyo Company, Ltd
- Merck & Co., Inc.
- Dainippon Sumitomo Pharma Co., Ltd.
- Novo Nordisk A/S
- Infinity Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- SkyePharma PLC
- Albany Molecular Research, Inc.
- BioLineRx, Ltd.
- Novartis AG
- Actelion Ltd
- ALK-Abello A/S
- Cephalon, Inc.
- Chiesi Farmaceutici SpA
- Glenmark Pharmaceuticals Ltd.
- Ono Pharmaceutical Co., Ltd.
- Orion Corporation
- Rigel Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries Limited
- OPKO Health, Inc.
- PARI Pharma GmbH
- Idera Pharmaceuticals, Inc.
- Lotus Pharmaceuticals, Inc.
- Almirall, S.A.
- Pacgen Biopharmaceuticals Corporation
- Palatin Technologies, Inc.
- Pharmaxis Ltd.
- Alexion Pharmaceuticals, Inc.
- Portola Pharmaceuticals, Inc.
- Cytokinetics, Inc
- Yuhan Corporation
- WhanIn Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- SciClone Pharmaceuticals, Inc.
- NeoStem, Inc.
- Array BioPharma Inc.
- Dynavax Technologies Corporation
- Phytopharm Plc
- Stallergenes S.A.
- Cytos Biotechnology AG
- Ahn-Gook Pharmaceutical Co., Ltd.
- Neurim Pharmaceuticals (1991) Ltd.
- Synairgen plc
- Galapagos NV
- Orexo AB
- e-Therapeutics plc
- InDex Pharmaceuticals AB
- Amphastar Pharmaceuticals, Inc.
- Verona Pharma Plc
- Morphotek, Inc.
- Alba Therapeutics Corporation
- Allergopharma Joachim Ganzer KG
- Immupharma Plc
- Palau Pharma S.A
- 7TM Pharma A/S
- Pieris AG
- Respiratorius AB
- Cosmix Molecular Biologicals GmbH
- REVOTAR Biopharmaceuticals AG
- Aquinox Pharmaceuticals Inc.
- Funxional Therapeutics Ltd
- ZaBeCor Pharmaceuticals
- Nostrum Pharmaceuticals, LLC
- Promedior, Inc.
- Oxagen Limited
- Heat Biologics, Inc.
- Pulmatrix, Inc.
- Opsona Therapeutics Ltd.
- Five Prime Therapeutics, Inc.
- MSM Protein Technologies, Inc.
- Indus Biotech Private Limited
- AIM Therapeutics Inc.
- Hydra Biosciences, Inc.
- Txcell SA
- Theraclone Sciences, Inc.
- Vantia Therapeutics
- Biotica Technology Ltd
- Monosol Rx, LLC
- NKT Therapeutics, Inc.
- Transtech Pharma, Inc.
- Xencor, Inc.
- Cornerstone Therapeutics Inc.
- Targacept, Inc.
- BaroFold, Inc.
- Sparsha Pharma International Pvt. Ltd.
- Cellceutix Corporation
- CBio Limited
- KaloBios Pharmaceuticals, Inc.
- AB Science
- Adamis Pharmaceuticals Corporation
- Laboratorios LETI S.L.
- NexBio, Inc.
- Endacea, Inc.
- Savara, Inc.
- Asmacure Limited
- Boehringer Ingelheim Pharmaceuticals, Inc.
- ISU ABXIS Co.,Ltd.
- Elevation Pharmaceuticals, Inc.
- N30 Pharmaceuticals
- Eurofarma
- Immune Technologies and Medicine
- Clarassance, Inc.
- Asthma – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- RG-3637 - Drug Profile
- indacaterol maleate - Drug Profile
- omalizumab - Drug Profile
- reslizumab - Drug Profile
- Flutiform - Drug Profile
- Flutiform - Drug Profile
- Relovair - Drug Profile
- Relovair - Drug Profile
- rabeprazole sodium - Drug Profile
- syncovair - Drug Profile
- Mitizax - Drug Profile
- Anti-Cholinergic Drug - Drug Profile
- fluticasone furoate - Drug Profile
- clarithromycin - Drug Profile
- Budesonide + Formoterol - Drug Profile
- masitinib - Drug Profile
- Staloral - Drug Profile
- azithromycin - Drug Profile
- omalizumab - Drug Profile
- MK-7243 - Drug Profile
- terbutaline sulphate - Drug Profile
- ciclesonide - Drug Profile
- rosiglitazone maleate - Drug Profile
- ADC-4022 - Drug Profile
- nedocromil - Drug Profile
- Acaroid - Drug Profile
- Spiriva - Drug Profile
- Formoterol + Fluticasone - Drug Profile
- Salmeterol + Fluticasone - Drug Profile
- Beclomethasone + Albuterol - Drug Profile
- Tiotropium + Salmeterol + Beclomethasone - Drug Profile
- beclomethasone dipropionate - Drug Profile
- beclomethasone dipropionate - Drug Profile
- Fluticasone Propionate + Montelukast - Drug Profile
- andolast - Drug Profile
- Budesonide + Formoterol - Drug Profile
- Fluticasone-Salmeterol Formulation - Drug Profile
- budesonide - Drug Profile
- Sereflo - Drug Profile
- tulobuterol patch - Drug Profile
- Anti-Inflammatory Program - Drug Profile
- Formoterol - Drug Profile
- IP-033 - Drug Profile
- Inactivated mycobacterium phlei - Drug Profile
- Flutican + Formoterol - Drug Profile
- Asthma Therapeutics – Drug Profile Updates
- Asthma Therapeutics – Discontinued Products
- Asthma Therapeutics - Dormant Products
- Asthma – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Asthma, H2 2012
- Products under Development for Asthma – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Development by Companies, H2 2012 (Contd..2)
- Number of Products under Development by Companies, H2 2012 (Contd..3)
- Number of Products under Development by Companies, H2 2012 (Contd..4)
- Number of Products under Development by Companies, H2 2012 (Contd..5)
- Number of Products under Development by Companies, H2 2012 (Contd..6)
- Number of Products under Development by Companies, H2 2012 (Contd..7)
- Number of Products under Development by Companies, H2 2012 (Contd..8)
- Number of Products under Development by Companies, H2 2012 (Contd..9)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Development by Companies, H2 2012 (Contd..2)
- Products under Development by Companies, H2 2012 (Contd..3)
- Products under Development by Companies, H2 2012 (Contd..4)
- Products under Development by Companies, H2 2012 (Contd..5)
- Products under Development by Companies, H2 2012 (Contd..6)
- Products under Development by Companies, H2 2012 (Contd..7)
- Products under Development by Companies, H2 2012 (Contd..8)
- Products under Development by Companies, H2 2012 (Contd..9)
- Products under Development by Companies, H2 2012 (Contd..10)
- Products under Development by Companies, H2 2012 (Contd..11)
- Products under Development by Companies, H2 2012 (Contd..12)
- Products under Development by Companies, H2 2012 (Contd..13)
- Products under Investigation by Universities/Institutes, H2 2012
- Alcon, Inc., H2 2012
- Johnson & Johnson, H2 2012
- Boehringer Ingelheim GmbH, H2 2012
- F. Hoffmann-La Roche Ltd., H2 2012
- Kyowa Hakko Kirin Co., Ltd., H2 2012
- Abbott Laboratories, H2 2012
- Amgen Inc., H2 2012
- AstraZeneca PLC, H2 2012
- GlaxoSmithKline plc, H2 2012
- Genentech, Inc., H2 2012
- Biotec Pharmacon ASA, H2 2012
- MedImmune LLC, H2 2012
- Daiichi Sankyo Company, Ltd, H2 2012
- Merck & Co., Inc., H2 2012
- Dainippon Sumitomo Pharma Co., Ltd., H2 2012
- Novo Nordisk A/S, H2 2012
- Infinity Pharmaceuticals, Inc., H2 2012
- Takeda Pharmaceutical Company Limited, H2 2012
- SkyePharma PLC, H2 2012
- Albany Molecular Research, Inc., H2 2012
- BioLineRx, Ltd., H2 2012
- Novartis AG, H2 2012
- Actelion Ltd, H2 2012
- ALK-Abello A/S, H2 2012
- Cephalon, Inc., H2 2012
- Chiesi Farmaceutici SpA, H2 2012
- Glenmark Pharmaceuticals Ltd., H2 2012
- Ono Pharmaceutical Co., Ltd., H2 2012
- Orion Corporation, H2 2012
- Rigel Pharmaceuticals, Inc., H2 2012
- Sun Pharmaceutical Industries Limited, H2 2012
- OPKO Health, Inc., H2 2012
- PARI Pharma GmbH, H2 2012
- Idera Pharmaceuticals, Inc., H2 2012
- Lotus Pharmaceuticals, Inc., H2 2012
- Almirall, S.A., H2 2012
- Pacgen Biopharmaceuticals Corporation, H2 2012
- Palatin Technologies, Inc., H2 2012
- Pharmaxis Ltd., H2 2012
- Alexion Pharmaceuticals, Inc., H2 2012
- Portola Pharmaceuticals, Inc., H2 2012
- Cytokinetics, Inc, H2 2012
- Yuhan Corporation, H2 2012
- WhanIn Pharmaceutical Co., Ltd., H2 2012
- Regeneron Pharmaceuticals, Inc., H2 2012
- SciClone Pharmaceuticals, Inc., H2 2012
- NeoStem, Inc., H2 2012
- Array BioPharma Inc., H2 2012
- Dynavax Technologies Corporation, H2 2012
- Phytopharm Plc, H2 2012
- Stallergenes S.A., H2 2012
- Cytos Biotechnology AG, H2 2012
- Ahn-Gook Pharmaceutical Co., Ltd., H2 2012
- Neurim Pharmaceuticals (1991) Ltd., H2 2012
- Synairgen plc, H2 2012
- Galapagos NV, H2 2012
- Orexo AB, H2 2012
- e-Therapeutics plc, H2 2012
- InDex Pharmaceuticals AB, H2 2012
- Amphastar Pharmaceuticals, Inc., H2 2012
- Verona Pharma Plc, H2 2012
- Morphotek, Inc., H2 2012
- Alba Therapeutics Corporation, H2 2012
- Allergopharma Joachim Ganzer KG, H2 2012
- Immupharma Plc, H2 2012
- Palau Pharma S.A, H2 2012
- 7TM Pharma A/S, H2 2012
- Pieris AG, H2 2012
- Respiratorius AB, H2 2012
- Cosmix Molecular Biologicals GmbH, H2 2012
- REVOTAR Biopharmaceuticals AG, H2 2012
- Aquinox Pharmaceuticals Inc., H2 2012
- Funxional Therapeutics Ltd, H2 2012
- ZaBeCor Pharmaceuticals, H2 2012
- Nostrum Pharmaceuticals, LLC, H2 2012
- Promedior, Inc., H2 2012
- Oxagen Limited, H2 2012
- Heat Biologics, Inc., H2 2012
- Pulmatrix, Inc., H2 2012
- Opsona Therapeutics Ltd., H2 2012
- Five Prime Therapeutics, Inc., H2 2012
- MSM Protein Technologies, Inc., H2 2012
- Indus Biotech Private Limited, H2 2012
- AIM Therapeutics Inc., H2 2012
- Hydra Biosciences, Inc., H2 2012
- Txcell SA, H2 2012
- Theraclone Sciences, Inc., H2 2012
- Vantia Therapeutics, H2 2012
- Biotica Technology Ltd, H2 2012
- Monosol Rx, LLC, H2 2012
- NKT Therapeutics, Inc., H2 2012
- Transtech Pharma, Inc., H2 2012
- Xencor, Inc., H2 2012
- Cornerstone Therapeutics Inc., H2 2012
- Targacept, Inc., H2 2012
- BaroFold, Inc., H2 2012
- Sparsha Pharma International Pvt. Ltd., H2 2012
- Cellceutix Corporation, H2 2012
- CBio Limited, H2 2012
- KaloBios Pharmaceuticals, Inc., H2 2012
- AB Science, H2 2012
- Adamis Pharmaceuticals Corporation, H2 2012
- Laboratorios LETI S.L., H2 2012
- NexBio, Inc., H2 2012
- Endacea, Inc., H2 2012
- Savara, Inc., H2 2012
- Asmacure Limited, H2 2012
- Boehringer Ingelheim Pharmaceuticals, Inc., H2 2012
- ISU ABXIS Co.,Ltd., H2 2012
- Elevation Pharmaceuticals, Inc., H2 2012
- N30 Pharmaceuticals, H2 2012
- Eurofarma, H2 2012
- Immune Technologies and Medicine, H2 2012
- Clarassance, Inc., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Asthma Therapeutics – Drug Profile Updates
- Asthma Therapeutics – Discontinued Products
- Asthma Therapeutics – Discontinued Products (Contd..1)
- Asthma Therapeutics – Discontinued Products (Contd..2)
- Asthma Therapeutics – Discontinued Products (Contd..3)
- Asthma Therapeutics – Discontinued Products (Contd..4)
- Asthma Therapeutics – Discontinued Products (Contd..5)
- Asthma Therapeutics – Dormant Products
- Asthma Therapeutics – Dormant Products (Contd..1)
- Asthma Therapeutics – Dormant Products (Contd..2)
- Asthma Therapeutics – Dormant Products (Contd..3)
- Asthma Therapeutics – Dormant Products (Contd..4)
- Asthma Therapeutics – Dormant Products (Contd..5)
- Asthma Therapeutics – Dormant Products (Contd..6)
- Asthma Therapeutics – Dormant Products (Contd..7)
- Asthma Therapeutics – Dormant Products (Contd..8)
- Asthma Therapeutics – Dormant Products (Contd..9)
- Asthma Therapeutics – Dormant Products (Contd..10)
- Asthma Therapeutics – Dormant Products (Contd..11)
- Asthma Therapeutics – Dormant Products (Contd..12)
- Asthma Therapeutics – Dormant Products (Contd..13)
- Asthma Therapeutics – Dormant Products (Contd..14)
- Asthma Therapeutics – Dormant Products (Contd..15)
- Asthma Therapeutics – Dormant Products (Contd..16)
- List of Figures
- Number of Products under Development for Asthma, H2 2012
- Products under Development for Asthma – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractAsthma – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Asthma - Pipeline Review, Global Markets Direct’s, 'Asthma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Asthma. Asthma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Asthma.
- A review of the Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Asthma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Asthma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
